Abstract: A method of manufacturing autologous cardiac lineage cells, the method includes receiving a patient-specific sample from a subject, producing a plurality of fibroblast cells as a function of the patient-specific sample, wherein producing the plurality of fibroblast cells includes transferring the patient-specific sample to a first growth media, generating a plurality of induced pluripotent stem cells (iPSCs) as a function of the plurality of fibroblast cells, wherein generating the plurality of iPSCs includes identifying a plurality of confluent iPSCs from the plurality of iPSCs, and differentiating the plurality of iPSCs into a plurality of cardiac lineage cells, wherein differentiating the plurality of iPSCs into a plurality of cardiac lineage cells includes performing a two-dimensional (2D) expansion process on the plurality of confluent iPSCs and performing a three-dimensional (3D) expansion process on the plurality of 2D-expended confluent iPSCs.

Abstract: In some embodiments, the present disclosure is directed to methods of reprogramming fibroblasts into induced pluripotent stem cells. In some embodiments, a method comprises obtaining fibroblasts, such as from a skin biopsy. In some embodiments, a method comprises reprogramming fibroblasts using a viral vector encoding reprogramming factors. In some embodiments, a method comprises expanding iPSC and identifying confluent iPSC.